HeyJaredPost-Hoc Live
Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack.
- Indexed episodes, last 90 days
- 5
- Latest publication
- Aug 7, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 16, 2026
Latest episodes
Live from Boston: How pharma thinks about China (opens the original)
Read excerpt
As large pharma companies increasingly turn to China to fill their pipelines, what long-term affect will it have on their strategy and operations? Pfizer's Andrew Baum shares the large drugmaker perspective on acquisitions, R&D, and how the industry could change in the years to come.Live from Endpoints’ China Biotech Debate: Boston on August 6, 2026.
Live from Boston: Investor math versus industrial priority (opens the original)
Read excerpt
Should investors embrace China’s fast-moving, fast-growing biotech sector, or should there be barriers to protect and preserve an industry that the US has dominated for decades? Ginkgo Bioworks CEO Jason Kelly, RA Capital Management's Peter Kolchinsky, and MIT professor Fiona Murray debate all sides of the flashpoint issue.Live from Endpoints’ China Biotech Debate: Boston on August 6, 2026.
Live from Boston: Has China changed how we build companies? (opens the original)
Read excerpt
In a world where promising drugs are quickly copied, improved on and raced into trials, is science still a differentiator? Strand Therapeutics CEO Jake Becraft and Roivant Sciences CEO Matt Gline discussed what actually counts as innovation, and if where the innovation happens matters for how the industry brings programs to patients. Live from Endpoints’ China Biotech Debate: Boston on August 6, 2026.
The case for — and against — an AZ-BMS megadeal (opens the original)
Read excerpt
AstraZeneca and Bristol Myers Squibb are reportedly in talks to combine, which would be one of the largest mergers the biopharma industry has ever seen. What could each company get out of the deal, and what would this deal mean for the industry overall? And are megamergers back? Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D
Record IPOs — with Parabilis and Kailera’s CEOs (opens the original)
Read excerpt
Kailera broke records with its $625 million IPO in April. But its high-water mark didn’t last long — in June, Parabalis made a $670 million debut, putting its own name on top of the record books. On Post-Hoc Live, we’re joined by Ron Renaud and Mathai Mammen, the CEOs of the companies, to talk about what it took to reach those heights. Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.